The U.S. Food and Drug Administration has approved Orzeyful, known generically as oveporexton, as a first-in-class oral orexin receptor 2 agonist designed to treat the full spectrum of narcolepsy type 1 symptoms in adults. Announced by Takeda, the regulatory decision introduces an entirely new class of targeted therapy for a chronic neurological condition that affects an estimated 120,000 people in the United States and is driven by an underlying deficiency of orexin.
Narcolepsy type 1, or NT1, involves narcolepsy with cataplexy alongside persistent 24-hour disruptions. Patients experience excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), cognitive symptoms and disrupted nighttime sleep. Until this regulatory milestone, available therapeutic options focused primarily on symptom relief rather than addressing the disease holistically.
“The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and how people feel on treatment,” said Julie Kim, president and chief executive officer of Takeda, in a corporate statement detailing the approval.
Clinical data supporting the regulatory decision derived from a comprehensive global clinical program, including the Phase 3 FirstLight and RadiantLight trials designated as studies TAK-861-3001 and TAK-861-3002. According to trial findings published by Takeda, adults receiving oveporexton demonstrated statistically significant and meaningful improvements across excessive daytime sleepiness, cataplexy and health-related quality of life when compared to participants receiving a placebo.
Clinical Efficacy and Safety Profile
The therapeutic innovation centers on an orexin treatment. Researchers note that targeting orexin receptor 2 alters how patients experience treatment compared to treatments that target symptom relief.
“Until now, people have managed narcolepsy type 1 with treatments that target symptom relief,” said Dr. Emmanuel Mignot, principal U.S. investigator in the ORZEYFUL Phase 3 program, highlighting the shift toward holistic disease management. “As the first and only approved orexin therapy to treat the broad spectrum of the disease, ORZEYFUL can enable a different kind of conversation in the doctor’s office about treatment options.”
Throughout clinical evaluation, oveporexton was generally well-tolerated, maintaining a safety profile consistent across clinical studies to date. Investigators identified the most common side effects reported by trial participants as trouble sleeping (insomnia), urinary urgency, urinary frequency, and excessive saliva.
Julie Flygare, President and CEO at Project Sleep, who lives with NT1, described the regulatory green light as a historic moment that expands treatment choices for affected communities.
Next Steps for Patient Access and Availability
While the regulatory hurdle has been cleared, patients will experience a waiting period before prescriptions reach commercial pharmacies. The medication requires evaluation by the Drug Enforcement Administration (DEA).
The controlled substance classification for the therapy is currently under review by the Drug Enforcement Administration. Company executives anticipate that scheduling will conclude within 90 days, at which point commercial launch preparations will finalize to make the treatment available to adult patients across the United States.
Worth a look